A Treatment Opportunity for Patients with Peripheral T-Cell Lymphoma

GC Cell announced on the 18th that its GCC2005 (CD5 CAR-NK), currently in development, has received approval for compassionate use from the Ministry of Food and Drug Safety.


This approval was granted following an application by Seoul National University Hospital to treat a patient with peripheral T-cell lymphoma for whom available therapeutic options were extremely limited after existing treatments. Seoul National University Hospital plans to administer GCC2005, the investigational clinical drug, to this patient for treatment purposes.

GC Cell's GCC2005 Receives Compassionate Use Approval at Seoul National University Hospital View original image

The compassionate use program allows the exceptional use of investigational clinical drugs that have not yet received regulatory approval from the Ministry of Food and Drug Safety for critically ill or terminal patients with life-threatening conditions and no alternative treatment options available.


GCC2005 is an allogeneic CD5-targeting CAR-NK cell therapy candidate being developed by GC Cell with the goal of becoming a globally innovative new drug. The company has completed dosing for participants in the phase 1a clinical trial in Korea and is preparing to initiate phase 1b.



A GC Cell official stated, "We will work closely with the Seoul National University Hospital research team to ensure the smooth treatment of patients, and will continue to pursue the clinical and global development strategy of GCC2005."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing